Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate GSK2190915 in Subjects With Mild Asthma

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: December 8, 2008
Last updated: October 11, 2016
Last verified: October 2016
This study will evaluate the safety and effect of repeat oral doses of GSK2190915 on lung function in mild asthmatics using a number of clinical and biological markers of efficacy.

Condition Intervention Phase
Drug: GSK2190915
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Early Asthmatic Response [ Time Frame: 0-2 hours after allergen challenge on Day 3 of each treatment period. ]

Secondary Outcome Measures:
  • Lung function as measured by FEV1 [ Time Frame: Days 1 and 3 ]
  • Assess safety and tolerability [ Time Frame: Throughout study ]

Enrollment: 17
Study Start Date: December 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 3 day repeat dose Drug: GSK2190915
Investigational Product


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2)
  • Female subjects must be of non childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophrectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 40 pg/ml (<140 pmol/L) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  • Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 5 terminal half-lives post-last dose.
  • Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation.
  • Pre-bronchodilator FEV1 >70% of predicted at screening.
  • Subjects who are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of <= 10 pack years.

[number of pack years = (number of cigarettes per day/20) x number of years smoked]

  • Demonstration of a positive wheal and flare reaction (>= 3 mm relative to negative control) to at least one allergen from a battery of allergens (including house dust mite, grass pollen and cat hair) on skin prick testing at screening, or within 12 months of study start.
  • Methacholine challenge PC20 < 8 mg/mL at screening or previous (in last 6 months) AMP, histamine or methacholine challenge that confirms the diagnosis of asthma
  • Screening allergen challenge demonstrates that the subject experiences an early asthmatic response. The early asthmatic response must include a fall in FEV1 of >= 20% from the post saline value, on at least one occasion, between 5 and 30 minutes after the final concentration of allergen. Data obtained from screening for LPA111834 may be used for this criteria.
  • Signed and dated written informed consent is obtained from the subject
  • The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria:

  • Past or present disease, which as judged by the investigator or medical monitor, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease
  • Clinically significant abnormalities in safety laboratory analysis at screening.
  • Subject has known history of hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg.
  • Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication
  • History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures
  • Symptomatic with hay fever at screening or predicted to have symptomatic hay fever during the time of study
  • Administration of oral or injectable steroids within 5 weeks of screening or intranasal and/or inhaled steroids within 4 weeks of the screening visit.
  • Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines and anti-asthma, anti-rhinitis or hay fever medication, other than short acting inhaled beta-agonists and paracetamol (up to 4 g per day) for the treatment of minor ailments eg headache from 14 days before screening until the follow-up visit.
  • Unable to abstain from short acting beta agonists within 8 hours prior to an allergen challenge, dosing with study drug or any lung function assessment.
  • If, after 2 concurrent administrations of saline during the allergen challenge at screening the subjects still have a fall in FEV1 of greater than 10%.
  • The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day.
  • History of being unable to tolerate or complete allergen challenge tests.
  • Subject is undergoing allergen desensitisation therapy.
  • There is a risk of non-compliance with study procedures.
  • History of blood donation (500 mL) within 3 months of starting the clinical study.
  • The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.
  • The subject has a screening QTc value of >450msec, PR interval outside the range 120 to 220msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T-wave).
  • The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
  • The subject has tested positive for HIV antibodies.
  • The subject has a positive pre-study urine cotinine/ breath carbon monoxide test or urine drug or urine or breath alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00812773

United Kingdom
GSK Investigational Site
London, United Kingdom, NW10 7EW
GSK Investigational Site
London, United Kingdom, W1G 8HU
GSK Investigational Site
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Study Data/Documents: Dataset Specification  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Study Protocol  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Annotated Case Report Form  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register
Statistical Analysis Plan  This link exits the site
Identifier: 112356
For additional information about this study please refer to the GSK Clinical Study Register

Responsible Party: GlaxoSmithKline Identifier: NCT00812773     History of Changes
Other Study ID Numbers: 112356
Study First Received: December 8, 2008
Last Updated: October 11, 2016
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through following the timelines and process described on this site.

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on May 22, 2017